检索结果-南通市图书馆

Whole exome sequencing identifies risk variants associated with intracranial epidermoid cyst deterioration:A case report

引用

World Journal of Clinical Oncology 2024年第11期15卷 1428-1434页

作者： Zhao-Na Song Yan Cheng Dan-Dan Wang Ming-Jun Li Xiang-Rong Zhao Fa-Wang Li Zhen Liu Xiao-Ru Zhu Xiao-Dong Jia Yu-Fang Wang Feng-Fan Liang Joint Laboratory for Translational Medicine Research Liaocheng People's HospitalLiaocheng 252000Shandong ProvinceChina Harbin Genars Technology Co. Ltd.Harbin 150060Heilongjiang ProvinceChina department of radiotherapy Liaocheng People's HospitalLiaocheng 252000Shandong ProvinceChina department of Medical laboratory Qilu Hospital of Shandong University Dezhou HospitalDezhou 253600Shandong ProvinceChina

BACKGROUND Intracranial epidermoid cyst(IEC)transformation to malignant squamous cell carcinoma(SCC)is extremely rare,and its etiology is yet ***,SCC is treated by performing surgery,followed by a combination of radiotherapy and *** is crucial to identify efficient and trustworthy therapeutic targets for SCC to improve its diagnosis,prognosis,and *** SUMMARY In this study,we report the case of a 47-year-old female patient with SCC,which progressed from IEC in the left internal capsule *** patient was sought treatment at our hospital for severe diplopic vision,accompanied with speech disorder and memory *** on the clinical and postoperative pathology,this patient was finally diagnosed with *** identify disease-causing variants,whole exome sequencing(WES)was performed on the *** revealed two pathogenic missense mutations on Gap junction protein beta 2(GJB2)(c.257C>T)and Toll-like receptor 2(TLR2)(c.1039A>G),*** This study provided the first clinical evidence for demonstrating the role of GJB2 and TLR2 in IEC development and *** further confirmed WES as a robust and reliable technique for underlying rare and complex disease-related genetic factor identification.

关键词： Intracranial epidermoid cyst Squamous cell carcinoma Whole exome sequencing Variants Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Bcl-2 expression significantly correlates with thymidylate synthase expression in colorectal cancer patients

引用

World Journal of Gastroenterology 2008年第40期14卷 6218-6223页

作者： Riyad Bendardaf Raija Ristmaki Kari Syrjnen Seppo Pyrhnen department of Oncology and radiotherapy Turku University Central Hospital

AIM: To examine the expression of thymidylate synthase (TS) and oncoprotein Bcl-2 in advanced colorectal cancer (CRC) patients,and to determine their mutual relationship,association to therapeutic response and impact on disease ***: Tumor samples from 67 patients with CRC,who were treated at advanced stage with either irinotecan alone or in combination with 5-fluorouracil/ leucovorin,were analyzed for expression of TS and Bcl-2 using ***: A significant linear correlation between lower expression levels of Bcl-2 and lower levels of TS expression was found (P = 0.033).Patients with high levels of both TS and Bcl-2 expression had a significantly longer disease-free survival (DFS) (42.6 mo vs 5.4 mo,n = 25) than those with low TS/Bcl-2 index (P = 0.001).Tumors with low levels of both TS and Bcl-2 were associated with a longer survival with metastasis (WMS) interval in the whole patients group (n = 67,P = 0.035).TS/Bcl-2 index was not significantly related to disease-specific ***: The present data suggest that CRC patients with low TS/Bcl-2 demonstrate a significantly shorter DFS and longer WMS.

关键词： Thymidylate synthase Bcl-2 Colorectal cancer Disease-free survival Survival with metastaseis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Conversion therapy of a giant hepatocellular carcinoma with portal vein thrombus and inferior vena cava thrombus:A case report and review of literature

引用

World Journal of Clinical Cases 2024年第16期12卷 2847-2855页

作者： Wen-Jie Song Jian Xu Ye Nie Wei-Min Li Jian-Ping Li Li Yang Meng-Qi Wei Kai-Shan Tao department of Hepatobiliary Surgery Xijing HospitalAir Force Medical UniversityXi'an 710032Shaanxi ProvinceChina department of radiotherapy The First Affiliated Hospital of the Fourth Military Medical UniversityXi'an 710032Shaanxi ProvinceChina State Key Laboratory of Cancer Biology Department of PathologyXijing Hospital and School of Basic MedicineXijing HospitalAir Force Medical UniversityXi'an 710000Shaanxi ProvinceChina department of Radiology Xijing HospitalAir Force Medical UniversityXi'an 710032Shaanxi ProvinceChina

BACKGROUND The prognosis of hepatocellular carcinoma(HCC)combined with portal and hepatic vein cancerous thrombosis is poor,for unresectable patients the combination of targeted therapy and immune therapy was the first-line recommended treatment for advanced HCC,with a median survival time of only about 2.7-6 *** this case report,we present the case of a patient with portal and hepatic vein cancerous thrombosis who achieved pathologic complete response after conversion *** SUMMARY In our center,a patient with giant HCC combined with portal vein tumor thrombus and hepatic vein tumor thrombus was treated with transcatheter arterial chemoembolization(TACE),radiotherapy,targeted therapy and immunotherapy,and was continuously given icaritin soft capsules for oral *** 7 months of conversion therapy,the patient's tumor shrank and the tumor thrombus subsided *** pathology of surgical resection was in complete remission,and there was no progression in the postoperative follow-up for 7 months,which provided a basis for the future strategy of combined conversion *** In this case,atezolizumab,bevacizumab,icaritin soft capsules combined with radiotherapy and TACE had a good *** patients with hepatocellular carcinoma combined with hepatic vein/inferior vena cava tumor thrombus,adopting a high-intensity,multimodal proactive strategy under the guidance of multidisciplinary team(MDT)is an important attempt to break through the current treatment dilemma.

关键词： Hepatocellular carcinoma Icaritin Conversion Downstaging Portal vein thrombus Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated,EGFR-mutated,advanced non-small cell lung cancer:data froma randomized phase III trial(AENEAS)

引用

Cancer Communications 2024年第9期44卷 1005-1017页

作者： Shun Lu Xiaorong Dong Hong Jian Jianhua Chen Gongyan Chen Yuping Sun Yinghua Ji ZipingWang Jianhua Shi Junguo Lu Shaoshui Chen Dongqing Lv Guojun Zhang Chunling Liu Juan Li Xinmin Yu Zhong Lin Zhuang Yu ZhehaiWang Jiuwei Cui Xingxiang Xu Jian Fang Jifeng Feng Zhi Xu RuiMa Jie Hu Nong Yang Xiangdong Zhou XiaohongWu Chengping Hu Zhihong Zhang You Lu Yanping Hu Liyan Jiang Qiming wang Renhua Guo Jianying Zhou Baolan Li Chunhong Hu Wancheng Tong Helong Zhang LinMa Yuan Chen Zhijun Jie Yu Yao Longzhen Zhang JieWeng Weidong Li Jianping Xiong Xianwei Ye Jianchun Duan Haihua Yang Meili Sun HongyingWei JiaweiWei Zheyu Zhang QiongWu department of Medical Oncology Shanghai Chest Hospital Shanghai JiaoTong UniversityShanghaiP.R.China Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and TechnologyWuhanHubeiP.R.China department of Medical Oncology-Chest Hunan Cancer Hospital&The Affiliated Cancer Hospital of Central South University Xiangya School of MedicineChangshaHunanP.R.China Thoracic OncologyMedicine HarbinMedical University Cancer HospitalHarbinHeilongjiangP.R.China department of Oncology Jinan Central HospitalJinanShandongP.R.China department of Oncology First Affiliated Hospital of Xinxiang Medical UniversityXinxiangHenanP.R.China department of Chest Medicine Beijing Cancer HospitalBeijingP.R.China department of Internal Medicine Linyi Cancer HospitalLinyiShandongP.R.China department of Respiratory Medicine Nantong Tumor HospitalNantongJiangsuP.R.China department of Oncology Binzhou Medical University HospitalBinzhouShandongP.R.China Breath Internal Medicine Taizhou Hospital of Zhejiang ProvinceLinhaiZhejiangP.R.China department of Respiration The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenanP.R.China department of Lung Internal Medicine Affiliated Tumor Hospital of Xinjiang Medical UniversityUrumqiXinjiangP.R.China department of Thoracic Oncology Sichuan Cancer HospitalChengduSichuanP.R.China Thoracic Medical Oncology Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)HangzhouZhejiangP.R.China department of Thoracic Oncology The Fifth Subsidiary Sun Yat-sen University HospitalZhuhaiGuangdongP.R.China department of Oncology The Affiliated Hospital of QingdaoUniversityQingdaoShandongP.R.China department of Oncology Shandong Cancer HospitalJinanShandongP.R.China department of Oncology The First BethuneHospital of Jilin UniversityChangchunJilinP.R.China department of Respiration Northern Jiangsu People’s Hospital Affiliated to Yangzhou UniversityYangzhouJiangsuP.R.China department of Internal

Background:The initial randomized,double-blinded,actively controlled,phase III ANEAS study(NCT03849768)demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first-line therapy in epidermal growth factor receptor(EGFR)-mutated advanced non-small cell lung cancer(NSCLC).Metastatic disease in the central nervous system(CNS)remains a challenge in the management of *** study aimed to compare the efficacy of aumolertinib versus gefitinib among patients with baseline CNS metastases in the ANEAS ***:Eligible patients were enrolled and randomly assigned in a 1:1 ratio to orally receive either aumolertinib or gefitinib in a double-blinded *** with asymptomatic,stable CNS metastases were ***-up imaging of the same modality as the initial CNS imaging was performed every 6 weeks for 15 months,then every *** responsewas assessed by a neuroradiological blinded,independent central review(neuroradiological-BICR).The primary endpoint for this subgroup analysis was CNS progression-free survival(PFS).Results:Of the 429 patients enrolled and randomized in the ANEAS study,106 patients were found to have CNS metastases(CNS Full Analysis Set,cFAS)at baseline by neuroradiological-BICR,and 60 of them had CNS target lesions(CNS Evaluable for Response,cEFR).Treatment with aumolertinib significantly prolonged median CNS PFS compared with gefitinib in both cFAS(29.0 vs.8.3 months;hazard ratio[HR]=0.31;95%confidence interval[CI],0.17-0.56;P<0.001)and cEFR(29.0 vs.8.3 months;HR=0.26;95%CI,0.11-0.57;P<0.001).The confirmed CNS overall response rate in cEFRwas 85.7%and 75.0%in patients treated with aumolertinib and gefitinib,*** risk analysis showed that the estimated probability of CNS progression without prior non-CNS progression or death was consistently lower with aumolertinib than with gefitinib in patients with and without CNSmetastases at *** new safety findings were ***:The

关键词： aumolertinib brain metastasis non-small cell lung cancer third-generation EGFR-TKI

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

SALIRI-based(raltitrexed plus irinotecan)therapy as a second-line treatment for patients with metastatic colorectal cancer(SALLY):A prospective,multicenter,non-interventional,registry study

引用

Cancer Communications 2024年第8期44卷 910-914页

作者： Shuqui Qin Jin Li Aiping Zhou Yanqiao Zhang Xianglin Yuan Liangjun Zhu Baoli Qin Shan Zeng Lin Shen Ying Yuan Weibo Wang Jun Liang Xianwen Zhang Feng Ye Ping Chen HuaizhangWang Zhenyan Yu Lu Yue Yong Fang Jianping Xiong Jianwei Yang Yiye Wan Xianli Yin Wenling Wang Nong Xu XiaohongWang Zemin Xiao Huafang Su YingWang Kangsheng Gu Shuiping Tu Zishu Wang Bo Liu Xiaohua Hu Weixian Liu Xiaofeng Li department of Oncology Nanjing Tianyinshan HospitalNanjingJiangsuP.R.China department of Medical Oncology Shanghai East HospitalShanghaiP.R.China department of Medical Oncology Cancer Hospital Chinese Academy of Medical SciencesBeijingP.R.China department of Gastroenterology Harbin Medical University Cancer HospitalHarbinHeilongjiangP.R.China department of Medical Oncology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiP.R.China department of Medical Oncology Jiangsu Cancer HospitalNanjingJiangsuP.R.China department of Gastroenterology Liaoning Cancer Hospital&InstituteShenyangLiaoningP.R.China department of Oncology Xiangya HospitalCentral South UniversityChangshaHunanP.R.China department of Medical Oncology Beijing Cancer HospitalBeijingP.R.China department of Medical Oncology The Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiangP.R.China department of Chemotherapy Shandong Provincial HospitalJinanShandongP.R.China department of Medical Oncology Peking University International HospitalBeijingP.R.China department of Medical Oncology Northern Jiangsu People’s HospitalYangzhouJiangsuP.R.China department of Medical Oncology The First Affiliated Hospital of Xiamen UniversityXiamenFujianP.R.China department of Medical Oncology General Hospital of NingxiaMedical UniversityYinchuanNingxiaP.R.China department of Integrated Chinese andWestern Medicine Henan Cancer HospitalZhengzhouHenanP.R.China department of Medical Oncology Mudanjiang Tumor HospitalMudanjiangHeilongjiangP.R.China department of Oncology Qingdao Municipal Hospital(Group)QingdaoShandongP.R.China department of Medical Oncology Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhouZhejiangP.R.China department of Medical Oncology The First Affiliated Hospital of Nanchang UniversityNanchangJiangxiP.R.China department of Abdominal Oncology Fujian Cancer HospitalFuzhouFujianP.R.China department of Gastroent

Primary chemotherapy options for colorectal cancer(CRC)involve four key drugs:fluorouracils(5-FU),oxaliplatin,irinotecan and *** first-line regimen consists of 5-FU and leucovorin combined with oxaliplatin(FOLFOX),while the second-line regimen involves 5-FU and leucovorin combined with irinotecan(FOLFIRI)for metastatic CRC(mCRC)in China[1].

关键词： drugs chemotherapy FOLFIRI

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Imaging tumor hypoxia:Blood-borne delivery of imaging agents is fundamentally different in hypoxia subtypes

引用

Journal of Innovative Optical Health Sciences 2014年第2期7卷 12-17页

作者： Peter Vaupel Armulf Mayer department of Radioncology and radiotherapy University Medical Center 55131 MainzGermany

Dedicated to the memory of Professor Briton Chance on the ccasion of his 100th birthday(July24 th,2013),and remembering mary erciting discussions on the orygenation of breast cancer,ontumor hyporia in general and imaging of the orygenation status of malignant *** tissue subvolumes are a hallmark feat ure of solid malignant tumors,relevant for cancertherapy and patient outcome because they increase both the intrinsic aggressiveness of tumor cells and their resist ance to several commonly used anticancer *** mech-anisms leading to hypoxia are diverse,may coexist within the same tumor and are commonlygrouped according to the duration of their *** hypoxia is mainly caused by difusionlimitations resulting from enlarged intercapilary distances and adverse difusion geometriesand--to a lsser extent--by hypoxemia,compromised perfusion or long-lasting microregionalfow ***,acute hypoxia preferentilly results from transient disruptions in *** each of these features of the tumor microenvironment can contribute to a criticalreduction of oxy gen availability,the delivery of imaging agents(as well as nutrients and anti-cancer agents)may be compromised or remain unaffected,Thus,a critial appraisal of the ffectsof the various mechanisms leading to hypoxia with regard to the blood-bome delivery of imagingagents is necessary to judge their ability to correctly represent the hypoxic phenotype of solidmalignancies.

关键词： Delivery of imaging agents tumor hypoxia hypoxia subty pes,chronic hypoxia acutehypoxia.

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Feedback regulation between phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 and transforming growth factor β1 and prognostic value in gastric cancer

引用

World Journal of Gastroenterology 2020年第1期26卷 21-34页

作者： Qi Shao Zhi-Ming Chen department of Chemotherapy/radiotherapy Affiliated Hospital of Nantong University

BACKGROUND Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1(PREX1)was reported to be overexpressed in some cancers and involved in cancer development,but its expression and significance in gastric cancer remain *** To evaluate the expression of PREX1 in gastric cancer and its significance in the development of gastric cancer,especially to evaluate the potential mechanism of PREX1 in gastric *** Bioinformatic analysis was performed in order to examine the expression of PREX1 in gastric *** relationship between the survival rate of gastric cancer patients and PREX1 expression was assessed by Kaplan Meier *** Gene Set Enrichment Analysis and the correlation between PREX1 and transforming growth factor(TGF)β1 pathway-related mediators were evaluated by cBioPortal for Cancer *** blotting and reverse transcriptase polymerase chain reaction assay were used to test the role of TGFβ1 on the expression of *** blotting and dual-luciferase reporter system was used to evaluate the effect of PREX1 on the activation of TGFβ1 *** healing and Transwell assay were used to assess the effect of PREX1 on the metastasis activity of gastric cancer *** PREX1 was overexpressed in the gastric tumors,and the expression levels were positively associated with the development of gastric ***,the high expression of PREX1 revealed poor prognosis,especially for those advanced and specific intestinal gastric cancer ***1 was closely involved in the positive regulation of cell adhesion and positively correlated with TGFβ1-related ***,TGFβ1 could induce the expression of PREX1 at both the protein and mRNA ***,PREX1 could activate the TGFβ1 *** induced PREX1 could increase the migration and invasion activity of gastric cancer *** PREX1 is overexpressed in gastric cancer,and the high level of PREX1 predicts poor ***1 is closely assoc

关键词： Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 Gastric cancer High expression Poor prognosis Metastasis Transforming growth factorβ1 pathway

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Systemic therapy for cervical carcinoma–current status

引用

Chinese Journal of Cancer Research 2018年第2期30卷 209-221页

作者： Krystyna Serkies Jacek Jassem department of Oncology and radiotherapy Medical University of Gdańsk

Two major treatment modalities in cervical cancer are radiation therapy（RT） and surgery. Chemotherapy continues to be the main form of systemic therapy adjunctive to definitive local therapies, and is used for ***-based regimens, administered concurrently with both definitive and postoperative RT, were demonstrated to provide significant survival benefits, whereas the beneficial effect of concurrent chemoradiotherapy in later-stage disease was smaller. The role of chemotherapy in addition to RT in IB1/IIA1 cervical cancer patients not undergoing surgery remains undefined. Likewise, the role of chemotherapy in combination with postoperative RT for patients with intermediate-risk factors for recurrence has not yet been verified. The recent standard for chemoradiotherapy is cisplatin alone administered weekly. Other cisplatin-based or non-cisplatin-based regimens have not been subjected to large clinical studies. The benefits of consolidation chemotherapy after chemoradiation for locally advanced cervical cancer are still undetermined. Neoadjuvant cisplatin-based chemotherapy followed by surgery has shown survival benefits, however its role in the era of chemoradiotherapy remains unclear. The combination of cisplatin and paclitaxel is considered a standard regimen in the palliative setting. There is no standard of care for second-line systemic therapy in advanced cervical *** combined with palliative chemotherapy（cisplatin/paclitaxel or topotecan/paclitaxel） in the first-line treatment for recurrent/metastatic cervical cancer significantly improves overall survival when compared to chemotherapy alone. The role of immunotherapy in cervical cancer remains to be established. The optimal combined modality treatment including systemic therapy for cervical tumors of non-squamous histology remains a matter of debate. Ongoing accumulation of data on genomic and proteomic characteristics provides insight into the molecular heterogeneity of cervica

关键词： Cervical cancer chemotherapy targeted therapy immunotherapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Predicting distant metastasis in nasopharyngeal carcinoma using gradient boosting tree model based on detailed magnetic resonance imaging reports

引用

World Journal of Radiology 2024年第6期16卷 203-210页

作者： Yu-Liang Zhu Xin-Lei Deng Xu-Cheng Zhang Li Tian Chun-Yan Cui Feng Lei Gui-Qiong Xu Hao-Jiang Li Li-Zhi Liu Hua-Li Ma department of Nasopharyngeal Head and Neck Tumor radiotherapy Zhongshan City People's HospitalZhongshan 528400Guangdong ProvinceChina School of Public Health Sun Yat-sen UniversityGuangzhou 510060Guangdong ProvinceChina department of Radiology Sun Yatsen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and TherapyGuangzhou 510060Guangdong ProvinceChina

BACKGROUND Development of distant metastasis(DM)is a major concern during treatment of nasopharyngeal carcinoma(NPC).However,studies have demonstrated im-proved distant control and survival in patients with advanced NPC with the addition of chemotherapy to concomitant ***,precise prediction of metastasis in patients with NPC is *** To develop a predictive model for metastasis in NPC using detailed magnetic resonance imaging(MRI)*** This retrospective study included 792 patients with non-distant metastatic NPC.A total of 469 imaging variables were obtained from detailed MRI *** were stratified and randomly split into training(50%)and testing *** boosting tree(GBT)models were built and used to select variables for predicting DM.A full model comprising all variables and a reduced model with the top-five variables were *** performance was assessed by area under the curve(AUC).RESULTS Among the 792 patients,94 developed DM during *** number of metastatic cervical nodes(30.9%),tumor invasion in the posterior half of the nasal cavity(9.7%),two sides of the pharyngeal recess(6.2%),tubal torus(3.3%),and single side of the parapharyngeal space(2.7%)were the top-five contributors for predicting DM,based on their relative importance in GBT *** testing AUC of the full model was 0.75(95%confidence interval[CI]:0.69-0.82).The testing AUC of the reduced model was 0.75(95%CI:0.68-0.82).For the whole dataset,the full(AUC=0.76,95%CI:0.72-0.82)and reduced models(AUC=0.76,95%CI:0.71-0.81)outperformed the tumor node-staging system(AUC=0.67,95%CI:0.61-0.73).CONCLUSION The GBT model outperformed the tumor node-staging system in predicting metastasis in *** number of metastatic cervical nodes was identified as the principal contributing variable.

关键词： Nasopharyngeal carcinoma Distant metastasis Machine learning Detailed magnetic resonance imaging report Gradient boosting tree model

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Improved organs at risk segmentation based on modified U‐Net with self‐attention and consistency regularisation

引用

CAAI Transactions on Intelligence Technology 2024年第4期9卷 850-865页

作者： Maksym Manko Anton Popov Juan Manuel Gorriz Javier Ramirez Electronic Engineering department Igor Sikorsky Kyiv Polytechnic InstituteKyivUkraine department of Signal Theory Telematics and CommunicationsUniversity of GranadaGranadaSpain

Cancer is one of the leading causes of death in the world,with radiotherapy as one of the treatment *** planning starts with delineating the affected area from healthy organs,called organs at risk(OAR).A new approach to automatic OAR seg-mentation in the chest cavity in Computed Tomography(CT)images is *** proposed approach is based on the modified U‐Net architecture with the ResNet‐34 encoder,which is the baseline adopted in this *** new two‐branch CS‐SA U‐Net architecture is proposed,which consists of two parallel U‐Net models in which self‐attention blocks with cosine similarity as query‐key similarity function(CS‐SA)blocks are inserted between the encoder and decoder,which enabled the use of con-sistency *** proposed solution demonstrates state‐of‐the‐art performance for the problem of OAR segmentation in CT images on the publicly available SegTHOR benchmark dataset in terms of a Dice coefficient(oesophagus-0.8714,heart-0.9516,trachea-0.9286,aorta-0.9510)and Hausdorff distance(oesophagus-0.2541,heart-0.1514,trachea-0.1722,aorta-0.1114)and significantly outperforms the *** current approach is demonstrated to be viable for improving the quality of OAR segmentation for radiotherapy planning.

关键词： 3‐D computer vision deep learning deep neural networks image segmentation medical image processing object segmentation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：